162635-10-1

Basic information

• Product Name: 2,4,6-trichlorobenzoic-2',2',5'-trimethyl-1',3'-dioxane-5'-carboxylic anhydride
• Synonyms: 2,4,6-trichlorobenzoic-2',2',5'-trimethyl-1',3'-dioxane-5'-carboxylic anhydride
• CAS NO: 162635-10-1
• Molecular Weight: 381.64
• Mol File: 162635-10-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2,4,6-trichlorobenzoic-2',2',5'-trimethyl-1',3'-dioxane-5'-carboxylic anhydride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6-trichlorobenzoic-2',2',5'-trimethyl-1',3'-dioxane-5'-carboxylic anhydride(162635-10-1)
• EPA Substance Registry System: 2,4,6-trichlorobenzoic-2',2',5'-trimethyl-1',3'-dioxane-5'-carboxylic anhydride(162635-10-1)

Safety Data

• Hazardous Substances Data: 162635-10-1(Hazardous Substances Data)

Usage

Type

Synthetic chemical compound

Functional Groups

Chlorobenzoic
Trimethyl
Dioxane
Carboxylic anhydride

Reactivity

Highly reactive due to chlorinated benzene and anhydride functional groups

Toxicity

Potentially toxic due to its chemical composition

Applications

Industrial or research applications as a reagent or precursor in organic synthesis

Potential Risks

Environmental and health risks due to its chemical properties

Further Research

Necessary for better understanding its uses and associated hazards, along with safety evaluation.

Upstream product

• 4767-03-7 2,2-bis(hydroxymethyl)propionic acid 
• 16837-14-2 2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid 
• 4136-95-2 2,4,6-trichlorobenzoyl chloride 

Downstream Products

• 162635-04-3 temsirolimus 
• 1296664-68-0 C₆₁H₉₃NO₁₇ 
• 162635-03-2 rapamycin 42-ester with 2,2,5-trimethyl[1,3]dioxane-5-carboxylic acid 
• 909555-81-3 C₆₁H₉₇NO₁₅Si 

Relevant articles and documents

Method for preparing temsirolimus

The invention discloses a method for preparing temsirolimus. The method comprises the following steps: (1) preparing 2,2,5-trimethyl-5-carboxy-1,3-dioxane; (2) cooling the 2,2,5-trimethyl-5-carboxy-1,3-dioxane and dichloromethane to 0-5 DEG C under the protection of nitrogen, performing stirring for dissolving, adding DIPEA and 2,4,6-trichlorobenzoyl chloride, and carrying out a reaction to obtainan acid anhydride product; (3) adding the acid anhydride product to dichloromethane containing rapamycin and 4-(N,N-dimethylamino)pyridine, and carrying out a reaction; and (4) mixing a product obtained in step (3) with tetrahydrofuran containing p-toluenesulfonic acid, dropwise adding ethylene glycol at 0-5 DEG C, adding water after the reaction is finished, performing extraction by using ethylacetate, and washing and drying the extracted product to prepare the temsirolimus. The method has the advantages of simple preparation process, high yield, high purity and low cost, and is suitable for industrialized production.

Preparation method for temsirolimus

The invention provides a preparation method for temsirolimus. The preparation method comprises the following steps: step 1, dissolving 2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid in a solvent underan alkaline condition, dropwise adding a solution of 2,4,6-trichlorobenzoyl chloride under stirring at a normal temperature, after a reaction is completed, carrying out cooling, adding a rapamycin double-protection compound, then dropwise adding an alkaline solution, and carrying out a reaction so as to obtain a coupled intermediate; and step 2, dissolving the coupled intermediate into a solvent,carrying out cooling, dropwise adding an inorganic acid solution, and carrying out deprotection so as to obtain the temsirolimus. The preparation method provided by the invention has the advantages ofsimple process, easy operation, high reaction yield, few by-products and applicability to industrial production.

PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES

The invention relates to processes for the preparation of compound of CCI-779 having the Formula (I), which is useful as an antineoplastic agent. The invention further relates to certain novel intermediates useful in the preparation of compound of CCI-779 and processes for their preparation. The invention also relates to pharmaceutical compositions that include the compound of CCI-779, prepared according to the processes disclosed herein.